Product Description
Goserelin is a type of hormone therapy called luteinising hormone blocker. This means it stops the release of luteinising hormone (LH) from the pituitary gland. Goserelin is a treatment for people who have oestrogen receptor positive (ER positive) breast cancer. This means that the cancer has proteins (receptors) for the hormone oestrogen. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/goserelin-breast-cancer)
Mechanisms of Action: GnRH Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, China, France, India, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Endometriosis|Prostate Cancer
Phase 2: Breast Cancer|Lobular Carcinoma|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20230886 | P1 |
Completed |
Prostate Cancer |
2024-03-27 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20250216 | P1 |
Active, not recruiting |
Prostate Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| ESCALATE | P2 |
Not yet recruiting |
Triple Negative Breast Cancer |
2026-12-01 |
51% |
2024-01-31 |
Primary Endpoints|Start Date|Treatments |
| NePtune | P2 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2025-12-01 |
63% |
2024-06-28 |
Primary Endpoints|Treatments |
| 2019-004942-14 | P2 |
Completed |
Lobular Carcinoma |
2025-01-17 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| ROSALINE | P2 |
Active, not recruiting |
Lobular Carcinoma|Breast Cancer |
2025-01-01 |
12% |
2024-12-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| PREDICT-RT* | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2033-12-31 |
2025-03-08 |
Primary Endpoints |
|
| S65935 | P3 |
Recruiting |
Prostate Cancer |
2032-06-01 |
2025-05-02 |
Treatments |
|
| GUIDANCE | P3 |
Recruiting |
Prostate Cancer|Adenocarcinoma |
2026-11-11 |
2025-03-18 |
Primary Endpoints |
|
| EF 161 | P3 |
Completed |
Prostate Cancer |
2023-11-30 |
22% |
2025-04-18 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| Zoreline 3.6 mg goserelin subcutaneous implant (Novalon) in women with confirmed endometriosis | P3 |
Active, not recruiting |
Endometriosis |
2016-10-21 |
2022-03-13 |
Treatments |